Delivery Order SPE2DE24DA017-SPE2D625F0YBZ
- Not listed
- Arthrex Inc., a leading provider of minimally invasive orthopedic medical technologies, was awarded a fixed-price delivery order valued at $3,029.40 by the Defense Logistics Agency's Medical Supply Chain on July 24, 2025, for the ACP MAX PRP System with ACDA. The delivery order, which is not set-aside for any specific business category, has an ultimate completion date of July 29, 2025, and will be performed in Naples, Florida. This award represents a task order under Arthrex's broader Indefinite...
- Arthrex Inc., a Naples, Florida-based orthopedic medical device manufacturer, received a $52,879.14 fixed-price delivery order from the Defense Logistics Agency's Medical Supply Chain on August 4, 2025, for an ACP MAX PRP System with ACDA technology. This delivery order represents a task order under Arthrex's larger Indefinite Delivery Contract (SPE2DE24D0020) valued at $471 million and running through September 1, 2029. The contract carries no set-aside designation, reflecting Arthrex's...
- Arthrex Inc., a Naples, Florida-based orthopedic medical device manufacturer, received a delivery order from the Defense Logistics Agency's Medical Supply Chain on August 1, 2025, for the supply of ARTHREX ANGEL PRP Kits. This fixed-price delivery order, valued at $12,475.65 with economic price adjustment provisions, is scheduled for completion by August 6, 2025, and will be fulfilled at the company's Naples facility. The contract was awarded without any set-aside designation, reflecting...
- Arthrex Inc., a Naples, Florida-based leader in minimally invasive orthopedic medical technologies, received a fixed-price delivery order valued at $35,772 from the Defense Logistics Agency's Medical Supply Chain on August 14, 2025, for the ARTHREX ANGEL PRP Kit (US Tray). The contract, which carries an ultimate completion date of August 19, 2025, was awarded without a set-aside designation, reflecting Arthrex's competitive strength in the federal orthopedic medical device marketplace. The...
- Arthrex Inc., a Naples, Florida-based leader in minimally invasive orthopedic medical technologies, received a $12,520.20 fixed-price delivery order from the Defense Logistics Agency's Medical Supply Chain on August 7, 2025, for the ARTHREX ANGEL PRP Kit. The delivery order, which carries an ultimate completion date of August 12, 2025, was awarded without set-aside designation, reflecting Arthrex's competitive strength in the federal orthopedic medical device marketplace. This order represents a...
- Arthrex Inc., a Naples, Florida-based leader in minimally invasive orthopedic medical technologies, received a fixed-price delivery order valued at $3,577.20 from the Defense Logistics Agency's Medical Supply Chain on August 1, 2025, with an ultimate completion date of August 6, 2025. The delivery order covers the Arthrex ANGEL PRP Kit for the U.S. market, a specialized medical device used in orthopedic procedures. This award was not set aside for any specific business category, reflecting...
- Arthrex Inc., a leading orthopedic medical device manufacturer headquartered in Naples, Florida, received a $8,943 fixed-price delivery order from the Defense Logistics Agency's Medical Supply Chain on July 25, 2025, for the ARTHREX ANGEL PRP Kit (US Tray). The delivery order, which carries an ultimate completion date of July 30, 2025, was awarded without set-aside designation, reflecting Arthrex's strong competitive standing in the federal marketplace. The work will be performed in Naples,...
- Arthrex Inc., a Naples, Florida-based leader in minimally invasive orthopedic medical technologies, was awarded a $2,475 fixed-price delivery order on August 8, 2025, for the Arthrex ACP Double Syringe System. The contract, issued by the Defense Logistics Agency's Medical Supply Chain, carries an ultimate completion date of August 13, 2025, and represents a non-set-aside award. This delivery order falls under the company's larger Indefinite Delivery Contract (SPE2DE24D0020) with the Defense...
- Arthrex Inc., a leading developer of minimally invasive orthopedic medical technologies based in Naples, Florida, has been awarded a fixed-price delivery order valued at $25,122.10 by the Defense Logistics Agency's Medical Supply Chain. The contract, awarded on July 23, 2025, with an ultimate completion date of July 28, 2025, calls for the delivery of an ACD-A 13G Open Tip BMA Angel Kit—a specialized orthopedic surgical product related to Arthrex's ANGEL platelet-rich plasma (PRP) system. The...
- Arthrex Inc., a Naples, Florida-based leader in minimally invasive orthopedic medical technologies, received a $5,775 fixed-price delivery order from the Defense Logistics Agency's Medical Supply Chain on July 23, 2025, for the Arthrex ACP Double Syringe System. This delivery order, with an ultimate completion date of July 28, 2025, represents a task order under Arthrex's larger Indefinite Delivery Contract (SPE2DE24D0020) with the Defense Logistics Agency, valued at approximately $471 million...
- SPE2DE24DA017Indefinite Delivery Contract
- SPE2DE24DA017-SPE2D625F0YBZDelivery Order
Arthrex Inc., a Naples, Florida-based orthopedic medical device manufacturer, received a $1,817.64 delivery order from the Defense Logistics Agency's Medical Supply Chain on August 13, 2025, for an ACP MAX PRP (Autologous Conditioned Plasma Maximum Platelet-Rich Plasma) System with Autologous Conditioned Plasma technology. This fixed-price contract with economic price adjustment provisions is set to conclude by August 18, 2025, and represents a task order under Arthrex's larger Indefinite Delivery Contract (SPE2DE24D0020) with the Defense Logistics Agency, valued at approximately $471 million and running through September 2029. The delivery will be performed at Arthrex's facility in Naples, Florida. As a leading supplier of minimally invasive orthopedic surgical technologies to the Department of Defense and Department of Veterans Affairs, Arthrex continues to support government healthcare systems through its comprehensive contract vehicle. The ACP MAX PRP system is a biologics-based orthopedic product designed to enhance surgical outcomes in joint preservation and regenerative medicine procedures. This delivery order exemplifies Arthrex's established competitive position in federal procurement, with no set-aside designation applied, and reflects the company's ongoing role in providing advanced orthopedic solutions across the VA and DoD medical systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.8k | 8/13/25 |